Similar to OC, endometrial malignancies tend to carry favorable prognoses when early detection is realized. Diagnosis at a later stage, however, typically coincides with a poor prognosis and a ...
The results of an investigation into how we might better tailor therapy for ovarian cancer have been released. The goal of the study was to investigate the role of the hormone HE4 in modulating an ...
Ovarian cancer remains a significant challenge in women's health, with high mortality rates due to late-stage diagnosis. This webinar aims to provide healthcare professionals with an in-depth ...
Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would ...
Ovarian Cancer is the 9th most common cancer in the world 1, and Europe has the highest rates of ovarian cancer in the world 2. Although the cancer antigen 125 (CA 125) assay has been used for more ...
While the human epididymis protein 4 (HE4) has been previously identified as a blood biomarker of fibrosis, the relationship HE4 has with other blood biomarkers has not been established.
Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously working ...
Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results